Skip to content
BiologicalX

Comparison

Clomiphene vs Omega-3 (EPA/DHA)

Side-by-side of Clomiphene and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Clomiphene

  • SERM that blocks estrogen-receptor negative feedback at the hypothalamus, raising LH and FSH
  • FDA approved 1967 for ovulation induction in anovulatory women at 50 to 100 mg cycle days 5 to 9
  • Off-label in men at 12.5 to 25 mg daily raises endogenous testosterone while preserving fertility
  • Enclomiphene (trans-isomer) is preferred for male use; cleaner PK and less estrogenic side effect burden
  • Visual disturbances occur in ~1 to 2% of users; persistent symptoms warrant immediate cessation
  • Letrozole has displaced clomiphene as first-line ovulation induction in PCOS (Legro 2014)

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute Clomiphene Omega-3 (EPA/DHA)
Category pharmaceutical supplement
Also known as Clomid, clomiphene citrate, Serophene, enclomiphene fish oil, EPA, DHA, marine omega-3
Half-life (hr) 168 48
Typical dose (mg) 25 2000
Dosing frequency 5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label) 1 to 2 times daily with food
Routes oral oral
Onset (hr) 6 4
Peak (hr) 7 12
Molecular weight 405.96 302.45
Molecular formula C26H28ClNO C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Selective estrogen receptor modulator that antagonizes estrogen at the hypothalamus and pituitary, increasing GnRH and gonadotropin output, which drives gonadal steroidogenesis. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status Prescription only (FDA approved for ovulation induction; off-label in men) Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status banned allowed
DEA / Rx Rx only (not a controlled substance) Not scheduled
Pregnancy Category X; contraindicated in pregnancy Recommended at 200 to 600 mg DHA/day for fetal development
CAS 911-45-5 10417-94-4
PubChem CID 1548953 446284
Wikidata Q416785 Q207688

Safety profile

Clomiphene

Common side effects

  • hot flushes
  • mood changes
  • abdominal discomfort
  • breast tenderness
  • visual disturbances (rare)
  • headache

Contraindications

  • pregnancy
  • active liver disease
  • ovarian cysts (not PCOS-related)
  • uncontrolled thyroid or adrenal disorder
  • abnormal uterine bleeding of undetermined origin
  • hormone-sensitive cancer

Interactions

  • tamoxifen: competing SERM activity; not used together(moderate)
  • ospemifene: competing SERM activity(moderate)
  • anastrozole: additive estrogen reduction; sometimes combined in male protocols(minor)
  • TRT (exogenous testosterone): TRT suppresses HPT axis that clomiphene targets; do not combine(moderate)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Clomiphene is the right call when one of the conditionals below applies.

Edge case: If you want to avoid prescription-only, Omega-3 (EPA/DHA) is the more accessible choice.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Clomiphene only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Clomiphene and Omega-3 (EPA/DHA)?

Clomiphene and Omega-3 (EPA/DHA) differ in category (pharmaceutical vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Clomiphene or Omega-3 (EPA/DHA)?

Clomiphene half-life is 168 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack Clomiphene with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper